Visible Genetics, Glaxo Wellcome deal

VGIN completed for 900 patient samples the sequence of the HIV-1 protease gene and parts of the HIV-1 reverse transcriptase gene involved in drug resistance that will be used by Glaxo for HIV compounds under development. VGIN used its OpenGene DNA sequencing system running its Trugene HIV-1 Genotyping kit. ...